These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

972 related items for PubMed ID: 19049336

  • 1. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C.
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [Abstract] [Full Text] [Related]

  • 2. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
    Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C.
    J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
    [Abstract] [Full Text] [Related]

  • 3. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY.
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [Abstract] [Full Text] [Related]

  • 4. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X, Ominsky MS, Villasenor KS, Niu QT, Asuncion FJ, Xia X, Grisanti M, Wronski TJ, Simonet WS, Ke HZ.
    Endocrinology; 2018 Jan 01; 159(1):260-271. PubMed ID: 29069393
    [Abstract] [Full Text] [Related]

  • 5. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
    Tian X, Jee WS, Li X, Paszty C, Ke HZ.
    Bone; 2011 Feb 01; 48(2):197-201. PubMed ID: 20850580
    [Abstract] [Full Text] [Related]

  • 6. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
    Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.
    Endocrinology; 2011 Sep 01; 152(9):3312-22. PubMed ID: 21733832
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.
    Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.
    J Bone Miner Res; 2010 Dec 01; 25(12):2647-56. PubMed ID: 20641040
    [Abstract] [Full Text] [Related]

  • 8. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M, Dwyer D, Niu QT, Villasenor KS, Kurimoto P, Grisanti M, Han CY, Liu M, Li X, Ominsky MS, Ke HZ, Kostenuik PJ.
    Bone; 2014 Oct 01; 67():305-13. PubMed ID: 25093263
    [Abstract] [Full Text] [Related]

  • 9. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.
    Sampath TK, Simic P, Sendak R, Draca N, Bowe AE, O'Brien S, Schiavi SC, McPherson JM, Vukicevic S.
    J Bone Miner Res; 2007 Jun 01; 22(6):849-59. PubMed ID: 17352644
    [Abstract] [Full Text] [Related]

  • 10. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
    Armamento-Villareal R, Sheikh S, Nawaz A, Napoli N, Mueller C, Halstead LR, Brodt MD, Silva MJ, Galbiati E, Caruso PL, Civelli M, Civitelli R.
    J Bone Miner Res; 2005 Dec 01; 20(12):2178-88. PubMed ID: 16294271
    [Abstract] [Full Text] [Related]

  • 11. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.
    Meng XW, Liang XG, Birchman R, Wu DD, Dempster DW, Lindsay R, Shen V.
    J Bone Miner Res; 1996 Apr 01; 11(4):421-9. PubMed ID: 8992872
    [Abstract] [Full Text] [Related]

  • 12. Strain-dependent variations in the response of cancellous bone to ovariectomy in mice.
    Iwaniec UT, Yuan D, Power RA, Wronski TJ.
    J Bone Miner Res; 2006 Jul 01; 21(7):1068-74. PubMed ID: 16813527
    [Abstract] [Full Text] [Related]

  • 13. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats.
    Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS.
    Bone; 2010 Sep 01; 47(3):529-33. PubMed ID: 20561907
    [Abstract] [Full Text] [Related]

  • 14. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
    Ma YL, Hamang M, Lucchesi J, Bivi N, Zeng Q, Adrian MD, Raines SE, Li J, Kuhstoss SA, Obungu V, Bryant HU, Krishnan V.
    Bone; 2017 Apr 01; 97():20-28. PubMed ID: 27939957
    [Abstract] [Full Text] [Related]

  • 15. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
    Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ.
    Endocrinology; 2014 Dec 01; 155(12):4785-97. PubMed ID: 25259718
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.
    Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ.
    J Bone Miner Res; 2011 May 01; 26(5):1012-21. PubMed ID: 21542004
    [Abstract] [Full Text] [Related]

  • 17. [Anti-sclerostin antibodies].
    Okazaki R.
    Clin Calcium; 2011 Jan 01; 21(1):94-8. PubMed ID: 21187600
    [Abstract] [Full Text] [Related]

  • 18. Inhibiting the inhibitor: a new route to bone anabolism.
    Jilka RL.
    J Bone Miner Res; 2009 Apr 01; 24(4):575-7. PubMed ID: 19335216
    [No Abstract] [Full Text] [Related]

  • 19. Prevention of trabecular bone loss induced by estrogen deficiency by a selective p38alpha inhibitor.
    Caverzasio J, Higgins L, Ammann P.
    J Bone Miner Res; 2008 Sep 01; 23(9):1389-97. PubMed ID: 18442314
    [Abstract] [Full Text] [Related]

  • 20. The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin.
    French DL, Muir JM, Webber CE.
    Phytomedicine; 2008 Dec 01; 15(12):1069-78. PubMed ID: 18693096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.